ResMed Q2 2023 Earnings Report
Key Takeaways
ResMed Inc. reported a 16% increase in revenue to $1,033.7 million and a diluted earnings per share of $1.53 for the second quarter of fiscal year 2023. The company's performance was driven by increased production and delivery of flow generator devices to meet customer demand and the acquisition of MEDIFOX DAN.
Revenue increased by 16% to $1,033.7 million, or 20% on a constant currency basis.
Diluted earnings per share reached $1.53, with non-GAAP diluted earnings per share at $1.66.
The acquisition of MEDIFOX DAN expanded the company's SaaS business outside the U.S.
The company significantly increased production and delivery of flow generator devices.
ResMed
ResMed
ResMed Revenue by Segment
Forward Guidance
ResMed remains focused on delivering lifesaving therapy solutions and accelerating the adoption of digital health in sleep apnea, COPD, and out-of-hospital care.